CAPABILITIES
EFFICACY MODELS
Model list may be filtered by model type and organ
Cell line | Organ | Model Type | Mutations | Weeks from stratification to termination (average) |
|---|---|---|---|---|
22Rv1 | Prostate | Xenograft | KMT2D, PIK3CA, TP53 | 5 |
4T1 | Breast | Syngeneic | Unavailable | 4 |
786-0 | Renal | Xenograft | PTEN, TERT, TP53, VHL | N/A |
A-375 | Skin | Xenograft | BRAF, CDKN2A, TERT | 4 |
A20 | Blood | Syngeneic | Unavailable | N/A |
A431 | Skin | Xenograft | TP53, EGFR-PPARGC1A fussion | N/A |
A498 | Renal | Xenograft | PIK3CB, VHL | 5 |
A549 | Lung | Xenograft | KRAS, STK11, TP53 | 6 |
A673 | Sarcoma | Xenograft | BRAF, TP53, EWS-FLI1 fusion | 3 |
AB22 | Lung | Syngeneic | CDKN2A | N/A |
AGS | Gastric | Xenograft | CTNNB1, KRAS, PIK3CA, TP53 | 6 |
B16-F10 | Skin | Syngeneic | Unavailable | 2 |
BxPc-3 | Pancreatic | Xenograft | BRAF, KRAS, TP53 | 7 |
CHLA-06 | Brain | Xenograft | TP53 | 6 |
CT26 | Colon | Syngeneic | KRAS | 2.5 |
CT26.CL25 | Colon | Syngeneic | KRAS | 2.5 |
Caki-1 | Renal | Xenograft | RB1 | 4 |
Cloudman S91 | Skin | Syngeneic | Unavailable | N/A |
Colo-205 | Colon | Xenograft | APC, BRAF, CTNNB1, TP53 | 2.5 |
Colon-26 (MC26) | Colon | Syngeneic | Unavailable | 4 |
D4M3A | Skin | Syngeneic | Unavailable | 2 |
DLD-1 | Colon | Xenograft | APC, ACVR2A, B2M, EP300, KRAS, PIK3CA, TGFBR2, TP53 | 4 |
DU-145 | Prostate | Xenograft | CDKN2A, RB1, STK11, TP53 | 6 |
EMT6 | Breast | Syngeneic | Unavailable | 5 |
ES-2-luc | Ovarian | Xenograft | BRAF, PALB2, TERT, TP53 | 3.5 |
HCC1954 | Breast | Xenograft | PIK3CA, TP53, CLTC-VMP1 fusion | 7 |
HCT-116 | Colon | Xenograft | ACVR2A, BRCA2, CDKN2A, CTNNB1, EP300, KRAS, PIK3CA, PPM1D, TGFBR2, TP53 | 5 |
HT-29 | Colon | Xenograft | APC, BRAF, PIK3CA, SMAD4, TP53 | N/A |
HuCCT1 | Bile Duct | Xenograft | KRAS, MSH6, TP53 | 5 |
Huh-7 | Liver | Xenograft | KDR, POLD3, TERT, TP53 | 4 |
JIMT-1 | Breast | Xenograft | PIK3CA, TP53 | 8 |
JeKo-1 | Blood | Xenograft | TP53 | 5 |
LASCPC-01 | Prostate | Xenograft | Unavailable | 3 |
LNCaP | Prostate | Xenograft | AR, MEN1, PIK3R1, PTEN, TP53 | 4 |
Lewis Lung LLC1 | Lung | Syngeneic | Unavailable | 3 |
MBT-2 | Bladder | Syngeneic | Unavailable | 5.5 |
MC38 | Colon | Syngeneic | Unavailable | 4 |
MDA-MB-231 | Breast | Xenograft | CDKN2A, CDKN2B, BRAF, KRAS, TERT, TP53 | 4 |
MDA-MB-468 | Breast | Xenograft | PTEN, RB1, TP53 | N/A |
MIAPaCa-2 | Pancreatic | Xenograft | KRAS, TP53 | 8 |
MOLM-13 | Blood | Xenograft | FLT3, KMT2A-MLLT3 fusion | 14 |
NCI-H1703 | Lung | Xenograft | CDKN2A, TP53 | 3 |
NCI-H1975 | Lung | Xenograft | EGFR, PIK3CA, TP53 | 6 |
NCI-H460 | Lung | Xenograft | KRAS, PIK3CA, STK11, TP53 | 5 |
NCI-N87 | Gastric | Xenograft | ERBB3, TP53 | 6 |
OCI-AML-3 | Blood | Xenograft | DNMT3A, NRAS, NPM1 | 2 |
OCI-Ly1 | Blood | Xenograft | Unavailable | N/A |
OVCAR8 | Ovarian | Xenograft | CTNNB1, ERBB2, KRAS, TP53 | 8 |
P388 | Blood | Syngeneic | Unavailable | N/A |
PANC-1 | Pancreatic | Xenograft | KRAS, TP53 | 3 |
PC-3 | Prostate | Xenograft | TP53 | 4 |
SK-BR-3 | Breast | Xenograft | TP53 | 4 |
SK-N-FI | Brain | Xenograft | NF1, TP53 | 4 |
SK-N-MC | Sarcoma | Xenograft | TP53, EWS-FLI1 fusion | 3 |
SK-OV-3 | Ovarian | Xenograft | APC, FBXW7, PIK3CA, TP53 | 10 |
SKM-1 | Blood | Xenograft | ASXL1, BCORL1, EZH2, KRAS, TP53 | 3 |
SU-DHL-16 | Blood | Xenograft | Unavailable | 4 |
SW480 | Colon | Xenograft | APC, KRAS, TP53 | 4 |
TT | Thyroid | Xenograft | RET, TBX3 | 4 |
U-87MG | Brain | Xenograft | Unavailable | 3 |
U118-MG | Brain | Xenograft | IDH1, PTEN, TP53 | 6 |
UM-UC-3 | Bladder | Xenograft | KRAS, PARD3B, TERT, TP53 | N/A |
VcAP | Prostate | Xenograft | MLH1, TP53, TMPRss2-ERG fusion | N/A |
WITT (SK-Cha-1) | Bile Duct | Xenograft | Unavailable | N/A |
WM164 | Skin | Xenograft | BRAF | 6 |
YAPC | Pancreatic | Xenograft | KRAS, TP53 | N/A |
ADDITIONAL CAPABILITIES
-
Fluorescent and luminescent imaging
-
Pharmacokinetic studies
-
MTD and tolerability studies
-
Tumor and organ collection
-
Histology and animal pathology
-
Pharmacodynamic assays, including ELISA, Mesoscale/Luminex, PCR, flow cytometry, and sequencing
-
Complementary cell-based in vitro assays supporting in vivo studies
Need something outside the standard study design? Talk to us.
WHY WORK WITH
RINCON BIO?
DOMESTIC QUALITY. EXCEPTIONAL VALUE.
Rincon conducts studies at our U.S. facilities. Your work stays close, your IP stays protected, and communication stays direct. We bring the depth of expertise you’d expect from a major CRO without the administrative layers and overhead, so more of your budget goes directly toward the science.
DIRECT ACCESS
Work directly with the PhD running your study—not a rotating account manager. We stay responsive, flexible, and hands-on throughout the study.
Email: info@rinconbio.com
Tel: 760-713-6613
Utah:
3900 N Traverse Mountain Blvd
Suite 100
Lehi, UT 84043
California:
3156 Vista Way, Suite 220
Oceanside, CA 92056
